RxDoctor Payments Data

Nicole Rashid, MD

Ophthalmology · South Charleston, WVNPI 1932214939

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 98.4% of the total across 28 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 12 manufacturers reported payments, led by AbbVie at 40.4% of the total.

$1,252in general payments, 2019–2025

Across 28 payments — averaging $44.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$505
  • Alcon$345
  • Sun Pharmaceutical Industries Inc.$150
  • Novartis$58
  • Bausch & Lomb Americas Inc.$44
  • Oyster Point Pharma, Inc.$32
  • plus $118 from 6 others

What the payments were for

  • Food & beverage$1,23298%
  • Gifts$192%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,252 in reported general payments places this provider in the 60th percentile of 85 ophthalmology providers in West Virginia.

See all ophthalmology providers in West Virginia

Medicare billing

Part B allowed, 2024
$9,380
Medicare patients
85
Services billed
252

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine200$309,070
Cyclosporine46$23,816
LumiganBimatoprost42$21,513
XiidraLifitegrast13$17,736
TyrvayaVarenicline Tartrate12$10,323
RhopressaNetarsudil Mesylate30$10,029
ErythromycinErythromycin Base739$8,159
Alphagan PBrimonidine Tartrate20$7,673
CombiganBrimonidine Tartrate/Timolol23$6,791
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol42$3,727
Travoprost16$3,276
Brimonidine Tartrate20$2,473
Latanoprost99$869
Prednisolone Acetate15$825
Ketorolac Tromethamine22$822

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Alphagan P, Combigan$505$345,046285 claims
Bausch & Lomb Americas Inc.Xiidra$44$17,73613 claims
Oyster Point Pharma, Inc.Tyrvaya$32$10,32312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 85 ophthalmology providers in West Virginia.

Other ophthalmology in South Charleston

See the full list for West Virginia

Where these figures come from

Is this you, or does something look wrong? →